Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report.
Journal
Chemotherapy
ISSN: 1421-9794
Titre abrégé: Chemotherapy
Pays: Switzerland
ID NLM: 0144731
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
19
09
2023
accepted:
20
10
2023
medline:
2
11
2023
pubmed:
2
11
2023
entrez:
1
11
2023
Statut:
aheadofprint
Résumé
For primary cutaneous diffuse large B-cell lymphoma, leg-type (PC DLBCL-LT) there are no uniform recommendations for second-line treatment in case of relapse. Here we present the case of an elderly relapsed/refractory PC DLBCL-LT patient who obtained a prolonged clinical complete remission with lenalidomide. Lenalidomide as single agent led to an unexpected long complete response with manageable toxicity.
Identifiants
pubmed: 37913761
pii: 000534784
doi: 10.1159/000534784
doi:
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
The Author(s). Published by S. Karger AG, Basel.